| Literature DB >> 27226157 |
Titikorn Chunchai1,2, Bencharunan Samniang1,2, Jirapas Sripetchwandee1,2, Hiranya Pintana1,2, Wanpitak Pongkan1,2, Sirinart Kumfu1,2, Krekwit Shinlapawittayatorn1,2, Bruce H KenKnight1,3, Nipon Chattipakorn1,2, Siriporn C Chattipakorn1,4.
Abstract
Vagus nerve stimulation (VNS) therapy was shown to improve peripheral insulin sensitivity. However, the effects of chronic VNS therapy on brain insulin sensitivity, dendritic spine density, brain mitochondrial function, apoptosis and cognition in obese-insulin resistant subjects have never been investigated. Male Wistar rats (n = 24) were fed with either a normal diet (n = 8) or a HFD (n = 16) for 12 weeks. At week 13, HFD-fed rats were divided into 2 groups (n = 8/group). Each group was received either sham therapy or VNS therapy for an additional 12 weeks. At the end of treatment, cognitive function, metabolic parameters, brain insulin sensitivity, brain mitochondrial function, brain apoptosis, and dendritic spines were determined in each rat. The HFD-fed with Sham therapy developed brain insulin resistance, brain oxidative stress, brain inflammation, and brain apoptosis, resulting in the cognitive decline. The VNS group showed an improvement in peripheral and brain insulin sensitivity. VNS treatment attenuated brain mitochondrial dysfunction and cell apoptosis. In addition, VNS therapy increased dendritic spine density and improved cognitive function. These findings suggest that VNS attenuates cognitive decline in obese-insulin resistant rats by attenuating brain mitochondrial dysfunction, improving brain insulin sensitivity, decreasing cell apoptosis, and increasing dendritic spine density.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27226157 PMCID: PMC4880928 DOI: 10.1038/srep26866
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The metabolic parameters after 12-week of ND or HFD consumption.
| Metabolic parameters | 12-week ND | 12-week HFD |
|---|---|---|
| Body weight (g) | 475.55 ± 7.92 | 544.34 ± 5.83 |
| Food intake (g/day) | 21.90 ± 1.30 | 21.15 ± 0.87 |
| Plasma glucose (mg/dl) | 131.25 ± 6.82 | 127.47 ± 5.04 |
| Plasma insulin (ng/ml) | 2.76 ± 0.34 | 5.87 ± 0.55 |
| HOMA index | 23.76 ± 5.74 | 33.83 ± 4.53 |
*p < 0.05 in comparison with ND group.
The metabolic parameters after 12-week of VNS treatment in comparison with the sham group.
| Metabolic parameters | 12 weeks post-treatment | |
|---|---|---|
| Sham | VNS | |
| Body weight (g) | 613.34 ± 8.97 | 594.17 ± 10.83 |
| Food intake (g/day) | 19.28 ± 1.61 | 19.46 ± 1.22 |
| Visceral fat (g) | 61.01 ± 2.61 | 51.92 ± 3.53 |
| Plasma glucose (mg/dl) | 131.47 ± 9.60 | 134.46 ± 3.98 |
| Plasma insulin (ng/ml) | 4.85 ± 1.36 | 3.04 ± 0.42 |
| HOMA index | 30.93 ± 10.85 | 18.12 ± 2.37 |
| Plasma glucose AUC (AUCg) (mg/dl × min × 104) | 5.58 ± 0.27 | 4.70 ± 0.23 |
| Plasma total cholesterol (mg/dl) | 105.93 ± 6.34 | 81.42 ± 2.66 |
| Plasma total triglyceride (mg/dl) | 28.73 ± 3.05 | 19.64 ± 1.60 |
| HDL cholesterol (mg/dl) | 27.94 ± 1.67 | 27.39 ± 0.95 |
| LDL/VLDL cholesterol (mg/dl) | 70.17 ± 5.79 | 48.62 ± 1.63 |
*p < 0.05 in comparison with the sham group.
Figure 1The effects of VNS on brain insulin receptor function, characterized by insulin-induced LTD (A), and its signaling, such as the phosphorylation levels of insulin receptor (B) and the phosphorylation levels of Akt protein (C) Sham: sham-operated HFD-fed rats; VNS: VNS-treated HFD-fed rats (N = 8 of each group) *p < 0.05 in comparison with the sham group.
Figure 2The effects of VNS on brain mitochondrial function in obese-insulin resistant rats, including brain mitochondrial ROS production (A), brain mitochondrial membrane potential changes (B) and brain mitochondrial swelling (C). Representative images demonstrate the morphology of brain mitochondria using transmission electron microscopy at the original magnification of 25,000x (D) Sham: sham-operated HFD-fed rats; VNS: VNS-treated HFD-fed rats (N = 8 of each group) *p < 0.05 in comparison with the sham group.
Figure 3The effects of VNS on inflammation: plasma TNF-α level (A) and brain TNF-α level (B), brain MDA levels using HPLC system (C) and brain apoptosis including Bax/Bcl-2 ratio using western blot analysis (D) Sham: sham-operated HFD-fed rats; VNS: VNS-treated HFD-fed rats (N = 8 of each group) *p < 0.05 in comparison with the sham group.
Figure 4The effects of VNS on dendritic spine density.
The representative images from invert bright field of dendritic spines (A,D) The representative 3D rendering of dendritic spine density was constructed using the Filament Tracer module of the Imaris Suite 7.0® software to generate spine reconstructions of the acquired invert bright field z-stack images (B,E) The representative overlay images from invert bright field of dendritic spines and 3D rendering (C,F) Upper panel (A–C) showed the representative dendritic spine density of sham group. Lower panel (D–F) showed the representative dendritic spine density of VNS group. (G) The effect of VNS or sham on the number of dendritic spines at CA1 region of hippocampus. Sham: sham-operated HFD-fed rats; VNS: VNS-treated HFD-fed rats (N = 8 of each group) *p < 0.05 in comparison with the sham group.
Figure 5Learning and memory behavioral results from Morris Water Maze test.
Chronic HFD consumption caused cognitive impairment as indicated by increased time required to reach the platform in the acquisition test (A) and decreased time spent in the target quadrant in the probe test (B). VNS treatment attenuated cognitive decline, as shown by decreased time required to reach the platform (C) and increased time spent in the target quadrant (D). ND: 12-week-normal diet-fed rats; HFD: 12-week high fat-fed rats; Sham: sham-operated HFD-fed rats; VNS: VNS-treated HFD-fed rats (N = 8 of each group) *p < 0.05 in comparison with the ND-fed rats; †p < 0.05 in comparison with the sham group.
Figure 6The experimental protocol of the present study.